ReviewMolecular medicine reports2026
Diabetic keratopathy and nuclear proteins (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic keratopathy (DK) is an ocular complication of diabetes mellitus (DM). Driven by DM‑induced chronic hyperglycemia and its associated metabolic changes, DK is characterized by progressive damage to the corneal epithelium, nerves, stroma and endothelium, manifesting as corneal epitheliopathy, neuropathy, stromal lesions and endotheliopathy. Nuclear proteins (NPs) play essential roles in the regulation of gene expression and physiological activities in the nucleus, and have been implicated in the occurrence and development DM and its complications. The present review provides an overview of DK and highlights the role of core NPs in its pathogenesis, including peroxisome proliferator‑activated receptors, high‑mobility group box 1, enhancer of zeste homolog, phosphatase and tensin homolog and sirtuins. The review underscores that the roles of these NPs in DK remain incompletely understood and highlights the need for further mechanistic studies and clinical trials to advance DK management. Therefore, it is suggested that future research should focus on elucidating the molecular mechanisms of NPs in DK, and developing novel detection techniques and treatment strategies to provide more effective outcomes for patients with DK.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.